Imidazolidinones as NS3-serine protease inhibitors of...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S018700, C514S019300, C514S396000, C514S401000, C548S335100, C548S337100, C530S331000

Reexamination Certificate

active

06838475

ABSTRACT:
The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.

REFERENCES:
patent: 6407066 (2002-06-01), Dressen et al.
patent: WO 9817679 (1998-04-01), None
patent: WO 0009543 (2000-02-01), None
Shiba, Tetsuo Bulletin of the Chemical Society of Japan 41(11), 2748-53, 1968.*
Szirtes Journal of Medicinal Chemistry 29(9), 1654-8, 1986.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Imidazolidinones as NS3-serine protease inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazolidinones as NS3-serine protease inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidinones as NS3-serine protease inhibitors of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3398545

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.